• Te-Chun Hsieh, Yu-Chin Wu, Kuo-Yang Yen, Shan-Wen Chen, and Chia-Hung Kao.
• Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung City, Taiwan; Department of Biomedical Imaging and Radiological Science, College of Medicine, China Medical University, Taichung City, Taiwan.
• J Neuroimaging. 2014 May 1;24(3):266-72.

BackgroundThe current study aimed to evaluate whether therapy-related changes occurred in brain metabolism at an earlier stage during the course of anticancer therapy.MethodsWe recruited 14 non-diabetic male patients with newly diagnosed pharyngeal squamous cell carcinoma. We analyzed the patients' serial brain FDG PET/CT scans by SPM8 to establish whether any therapy-related changes had occurred in brain FDG metabolism, either during or after the course of therapy.ResultsDecreased metabolism was noted during the anticancer therapy, displaying a symmetric pattern involving bilateral basal ganglia and bilateral occipital lobes. The decrease in FDG metabolism in these regions persisted after the anticancer therapy had terminated. However, relative recovery of the metabolism was noted in the bilateral occipital lobes, whereas further deterioration was noted in bilateral basal ganglia.ConclusionsThe current study revealed that unappreciable changes in brain metabolism can occur during the early course of anticancer therapy, and persist even after therapy has terminated. Although the exact mechanism remains unclear, these changes may be related to the systemic effects of chemotherapy or radiotherapy as well as subclinical cancer-related depressive or adjustment mood disorder.Copyright © 2013 by the American Society of Neuroimaging.

44 keywords...

hide…